Hans K Hasselbalch

Hans K Hasselbalch

Clinical Professor

Member of:

  • Internal Medicine: Haematology


Publication year:
All
91 - 100 out of 133Page size: 10
Sort by: 1st author
  1. Published

    An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

    Grauslund, J. H., Holmström, M. O., Martinenaite, E., Lisle, T. L., Glöckner, H. J., Fassi, Daniel El , Klausen, U., Mortensen, R. E. J., Jørgensen, N., Kjær, L., Skov, V., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2023, In: Frontiers in Immunology. 14, 14 p., 1117466.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms

    Gotfredsen, K., Liisborg, C., Skov, V., Kjær, L., Hasselbalch, Hans Carl & Sørensen, Torben Lykke, 11 Mar 2023, In: Scientific Reports. 13, 1, p. 4077 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

    the PROUD-PV Study Group, T. P. S. G., 2023, In: Leukemia. 37, 10, p. 2129-2132 4 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  4. Published

    Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Grohmann-Izay, B., Hasselbalch, H. C., Kralovics, R., Kiladjian, J. J., Bauer, F., Berbec, N. & 41 others, Besses Raebel, C., Borbenyi, Z., Bumbea, H., Buxhofer-Ausch, V., Calbecka, M., Cayssials-Caylus, E., Cazzola, M., Cerna, O., Cucuianu, A., Dima, D. M., Forjan, E., Gheorghita, E., Greil, R., Hatalova, A., Hrubisko, M., Jakucs, J., Kaplan, P., Klymenko, S., Koschmieder, S., Lazaroiu, M., Lysa, T., Masliak, Z., Masszi, T., Mihaylov, G., Myasnikov, A., Platzbecker, U., Puyade, M., Rey, J., Roy, L., Schwarz, J., Skotnicki, A., Sokolova, I., Soroka-Wojtaszko, M., Starzak-Gwozdz, J., Stoeva, V., Torregrosa-Diaz, J. M., Vallova, A., Volodicheva, E., Warzocha, K., Willenbacher, E. & Wolf, D., 2020, In: The Lancet Haematology. 7, 3, p. e196-e208 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

    Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Hasselbalch, Hans Carl, Kralovics, R. & Kiladjian, J., 2020, In: HemaSphere. 4, 6, 4 p., e485.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

    Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M. & 23 others, Ho, V. T., Hobbs, G. S., Knudsen, T. A., Skov, V., Kjær, L., Larsen, T. S., Hansen, D. L., Lindsley, R. C., Hasselbalch, Hans Carl, Grauslund, J. H., Lisle, T. L., Met, Özcan, Wilkinson, P., Greenbaum, B., Sepulveda, M. A., Chan, T., Rampal, R., Andersen, Mads Hald, Abdel-Wahab, O., Bhardwaj, N., Wolchok, J. D., Mullally, A. & Merghoub, T., 2022, In: Science Translational Medicine. 14, 649, eaba4380.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

    Ghanima, W., Bussel, J. B., Junker, P., Hasselbalch, Hans Carl, Gudbrandsdottir, S., Boiocchi, L., Geyer, J. T., Orazi, A. & Feng, X., 1 Oct 2011, In: British Journal of Haematology. 155, 2, p. 248-255 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia

    Garabet, L., Ghanima, W., Monceyron Jonassen, C., Skov, V., Holst, R., Mowinckel, M., Hasselbalch, Hans Carl, A. Kruse, T., Thomassen, M., Liebman, H., Bussel, J. B. & Sandset, P. M., 2019, In: Platelets. 30, 2, p. 206-212

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Vascular diseases in patients with chronic myeloproliferative neoplasms: Impact of comorbidity

    Frederiksen, H., Szépligeti, S., Bak, M., Ghanima, W., Hasselbalch, Hans Carl & Christiansen, C. F., 2019, In: Clinical Epidemiology. 2019, 11, p. 955-967

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study

    Frederiksen, H., Farkas, D. K., Christiansen, C. F., Sørensen, H. T. & Hasselbalch, Hans Carl, 15 Dec 2011, In: Blood. 118, 25, p. 6515-6520 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...6 7 8 9 10 11 12 13 14 Next

ID: 2849472